The present application relates to compound A, namely 3- (3- (4- (1-aminocyclobutyl) phenyl) -5-phenyl-3H-imidazo [4,5-b] pyridin-2-yl) pyridin-2- Amine salt, solid form of Compound A free base or solid form of Compound A salt, amorphous form of Compound A free base or amorphous form of Compound A salt, crystalline form of Compound A free base or It relates to a crystalline form of a salt of compound A, a polymorph of compound A free base or a polymorph of salt of compound A, and an intermediate form of compound A free base or an intermediate form of salt of compound A. The application also relates to pharmaceutical compositions comprising these salts, solid forms, amorphous forms, crystalline forms, polymorphs or intermediate forms of the salts of Compound A free base or of Compound A. The present application provides methods for preparing solid, amorphous, crystalline, polymorphic, or intermediate forms of these salts, Compound A free base or Compound A salts.本出願は、化合物A、つまり3-(3-(4-(1-アミノシクロブチル)フェニル)-5-フェニル-3H-イミダゾ[4,5-b]ピリジン-2-イル)ピリジン-2-アミンの塩、化合物A遊離塩基の固体状形態または化合物Aの塩の固体状形態、化合物A遊離塩基の非晶質形態または化合物Aの塩の非晶質形態、化合物A遊離塩基の結晶形態または化合物Aの塩の結晶形態、化合物A遊離塩基の多型または化合物Aの塩の多型、および化合物A遊離塩基の中間型または化合物Aの塩の中間型に関する。本出願は同様に、これらの塩、化合物A遊離塩基のもしくは化合物Aの塩の固体状形態、非晶質形態、結晶形態、多型または中間型を含む薬学的組成物に関する。本出願は、これらの塩、化合物A遊離塩基のもしくは化合物Aの塩の固体状形態、非晶質形態、結晶形態、多型または中間型を調製するための方法を提供する。
